View in Other Languages

Alchemia Limited

ASX:ACL ISIN:AU000000ACL6

 Alchemia is a drug discovery and development company marketing FDA approved fondaparinux, an injectible antithrombotic in the US, as well as other major markets via partner Dr. Reddy's Laboratories. The Company is also developing a late stage oncology product pipeline with multiple ongoing trials through its proprietary HyACT drug delivery platform, which targets anti-cancer drugs to solid tumours. Lead asset HA-Irinotecan is in a pivotal Phase III clinical trial for the treatment of metastatic colorectal cancer. HA-Irinotecan is also in two Phase II investigator-led trials, one of which is in collaboration with Merck Serono combining HA-Irinotecan with Erbitux(R) (cetuximab). Alchemia is also exploring additional small molecule drug discovery targets via an internal discovery platform VAST, based on the Company's deep chemistry expertise. The VAST technology is being developed in collaboration with leading academic institutions and is partnered with AstraZeneca AB.

  

News

Alchemia Limited (ASX:ACL) Announces Half-year Results for Period Ended 31 December 2013

🕔2/18/2014 5:31:58 PM 3412

Alchemia Limited (ASX:ACL) a drug discovery and development company, is pleased to announce its half year results for the six months ended 31 December 2013.

Read Full Article

Asian Activities Report for September 28, 2011: Fletcher Building (ASX:FBU) Announce Major Supply Contract for the Queensland Coal Seam Gas Market

🕔9/28/2011 12:02:16 PM 7627

Asian Activities Report for September 28, 2011 includes: Fletcher Building Limited (ASX:FBU) said today that Iplex Pipelines has been awarded a A$120 million contract for the supply of polyethylene pipe; Integra Mining Limited (ASX:IGR) reported aircore drilling results from reconnaissance drilling in the Mt Monger area; African Iron Limited (ASX:AKI) provides an update on drilling activities at its 92%-owned Mayoko iron ore project in the Republic of Congo; Alchemia Limited (ASX:ACL) said today that its leading cancer product HA-Irinotecan has received very promising trial results; Tata Communications (BOM:500483) has become one of the few global carriers to extend its Global IP/VPN service offerings into Pakistan.

Read Full Article

Benitec Limited (ASX:BLT) Announce A Board and Senior Management Update

🕔3/29/2010 10:54:56 AM 8624

Benitec Limited (ASX:BLT) (PINK:BNIKF) announced today that Ms Sue MacLeman will step down from the role of Chief Executive Officer (CEO) and Managing Director to pursue other opportunities. She has agreed however to stay actively involved with Benitec as a Strategic Advisor at this exciting time for the Company. A transition arrangement has been put in place. Mr Mel Bridges and Dr John Chiplin will both move to Executive Director roles within the Company and the Board will be further strengthened in the coming months.

Read Full Article
###

27,953 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 4) (Last 30 Days: 43) (Since Published: 7333) 

Markets ASX:ACL

Company Data

    Fax
  • (07) 3340 0200 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Listed
  • 2003/12/23 

Social Media